{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03876197",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CVB2019-1"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2014-004349-29",
            "SecondaryIdType": "EudraCT Number"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Rigshospitalet, Denmark",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stem Cells for Radiation-induced Xerostomia",
      "OfficialTitle": "Follow-up Study of Safety and Efficacy in Subjects Who Participated in the Study of Intraglandular Mesenchymal Stem Cells in Patients With Radiation-induced Hyposalivation and Xerostomia (MESRIX)"
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2020",
      "OverallStatus": "Enrolling by invitation",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "August 1, 2020",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 1, 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 1, 2023",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "March 12, 2019",
      "StudyFirstSubmitQCDate": "March 13, 2019",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "March 15, 2019",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "October 20, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 22, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Charlotte Lynggaard",
        "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
        "ResponsiblePartyInvestigatorAffiliation": "Rigshospitalet, Denmark"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Rigshospitalet, Denmark",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "A prospective study for long-term follow-up (LTFU) to evaluate safety and efficacy in subjects who participated in the Phase 1/2 randomized placebo-controlled trial MESRIX.",
      "DetailedDescription": "This is a LTFU study to assess the long-term and late effects of treatment with MSCs or placebo given ultrasound-guided into the submandibular glands in subjects participating in the MESRIX trial. Study participants from the MESRIX trial will be invited for a clinical visit. The visit will include medical history, an ENT examination; measurements of the saliva production by sialometry, a Magnetic resonance imaging scan (MRI) and obtaining data on the patient-reported outcome with Xerostomia Questionnaire (XQ) and Visual-Analogue-Symptomatic scale (VAS). Subjects, who are not able or willing to attend a clinical visit, will be encouraged to fill out the Questionnaires online or on paper. If a study participant has deceased, information of the cause of death will be investigated in The Danish Register of Causes of Death"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Radiation Toxicity",
          "Xerostomia Due to Radiotherapy",
          "Dry Mouth",
          "Hyposalivation",
          "Mesenchymal Stem Cells",
          "Mesenchymal Stromal Cells",
          "Long Term Adverse Effects"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Xerostomia Due to Radiotherapy"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignInterventionModelDescription": "Long-term follow-up of Randomized controlled trial MESRIX",
        "DesignPrimaryPurpose": "Other",
        "DesignMaskingInfo": {
          "DesignMasking": "Triple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "30",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Autologous Adipose-derived mesenchymal stem cells",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Autologous adipose-derived mesenchymal stem cells transplanted intraglandular in patients with radiation-induced hyposalivation and xerostomia",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Autologous adipose-derived mesenchymal stem/stromal cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "2 ml placebo: Isotonic NaCl (0.9mg(ml) and human albumin (HA) 1%",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Autologous adipose-derived mesenchymal stem/stromal cells",
            "InterventionDescription": "Autologous adipose-derived mesenchymal stem/stromal cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Autologous Adipose-derived mesenchymal stem cells"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Placebo",
            "InterventionDescription": "Isotonic NaCl (0,9mg/ml) and human albumin (HA) 1%",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Safety: Serious Adverse Events (SAEs) and new chronic diseases",
            "PrimaryOutcomeDescription": "SAEs according to the ICH-GCP definition and new chronic diseases. For patients not attending the planned hospital visit consider searching The National Patient Register will be searched for registered SAEs. Number of patients",
            "PrimaryOutcomeTimeFrame": "5 years from randomization"
          },
          {
            "PrimaryOutcomeMeasure": "Overall survival",
            "PrimaryOutcomeDescription": "Overall survival is defined as the time from the intraglandular dose of the investigational product (MSCs or placebo) to the date of death or the date the subject is last known to be alive",
            "PrimaryOutcomeTimeFrame": "5 years from randomization"
          },
          {
            "PrimaryOutcomeMeasure": "Relapse of oropharyngeal cancer",
            "PrimaryOutcomeDescription": "Number of participants with relapse will be reported",
            "PrimaryOutcomeTimeFrame": "5 years from randomization"
          },
          {
            "PrimaryOutcomeMeasure": "New malignancies",
            "PrimaryOutcomeDescription": "Number of subjects who have new malignancies will be reported",
            "PrimaryOutcomeTimeFrame": "5 years from randomization"
          },
          {
            "PrimaryOutcomeMeasure": "Zoonotic Diseases",
            "PrimaryOutcomeDescription": "Number of subjects diagnosed Zoonotic Diseases will be reported",
            "PrimaryOutcomeTimeFrame": "5 years from randomization"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Patient-reported outcome measures-Health-related quality of life (HRQoL",
            "SecondaryOutcomeDescription": "Xerostomia Questionnaire (XQ) ( Median item scores for each of the 8 questions will be reported (score range 0-10) and the XQ summary/composite score (0-100))",
            "SecondaryOutcomeTimeFrame": "5 years from randomization"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAssessment of safety and treatment efficacy in subjects who were enrolled in the MESRIX Phase I/II clinical trial\nSubjects who were treated with either autologous mesenchymal stem cells or placebo\nSubjects who voluntarily decided to participate and signed the consent form after receiving explanations on the trial\n\nExclusion Criteria:\n\n1. Subjects who were not enrolled in the MESRIX trial",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "99 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Charlotte Lynggaard, MD",
            "OverallOfficialAffiliation": "Department of Otolaryngology, Rigshospitalet, Copenhagen, Denmark",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Department of Otolaryngology, University Hospital of Copenhagen",
            "LocationCity": "Copenhagen",
            "LocationCountry": "Denmark"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000014987",
            "ConditionMeshTerm": "Xerostomia"
          },
          {
            "ConditionMeshId": "D000069451",
            "ConditionMeshTerm": "Long Term Adverse Effects"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000012466",
            "ConditionAncestorTerm": "Salivary Gland Diseases"
          },
          {
            "ConditionAncestorId": "D000009059",
            "ConditionAncestorTerm": "Mouth Diseases"
          },
          {
            "ConditionAncestorId": "D000009057",
            "ConditionAncestorTerm": "Stomatognathic Diseases"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M16876",
            "ConditionBrowseLeafName": "Xerostomia",
            "ConditionBrowseLeafAsFound": "Xerostomia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M420",
            "ConditionBrowseLeafName": "Long Term Adverse Effects",
            "ConditionBrowseLeafAsFound": "Long-term Adverse Effects",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14437",
            "ConditionBrowseLeafName": "Salivary Gland Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11171",
            "ConditionBrowseLeafName": "Mouth Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11169",
            "ConditionBrowseLeafName": "Stomatognathic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC07",
            "ConditionBrowseBranchName": "Mouth and Tooth Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    }
  }
}